Story
Moderna Stock Reverses Gains, Closes 4% Lower on Report of Potential White House Vaccine Order

Moderna shares (NASDAQ:MRNA) reversed course to close sharply lower on Thursday after a report suggested the White House is considering an executive order that could impact U.S. vaccination schedules. The political uncertainty overshadowed a landmark regulatory approval for the company's mRNA-based influenza vaccine.
Political Headwinds Overshadow FDA Win
Moderna's stock ended the trading session down 4.2% after initially trading higher. The sell-off was triggered by a Bloomberg report stating that President Donald Trump is contemplating an executive order concerning vaccines and autism, which could be issued as soon as next week.
According to the report, while details are not yet clear, the order could potentially lead to a reduction in vaccination schedules for children. This news introduced significant uncertainty for vaccine manufacturers, with investors viewing Moderna as particularly exposed to any changes in U.S. vaccination policy.
Key Milestones for mRNA Platform
The market's negative reaction eclipsed what was otherwise a day of significant positive news for the biotechnology company, highlighting key progress in diversifying its mRNA platform beyond COVID-19.
Ad- Landmark Flu Vaccine Approval: The U.S. Food and Drug Administration (FDA) approved mFLUSIVA (mRNA-1010), the first-ever mRNA-based seasonal influenza vaccine authorized in the United States. The approval covers adults aged 50 and older and allows Moderna to begin supplying the vaccine for the 2026–2027 season.
- Ebola Vaccine Trial: Moderna also announced the start of a Phase 1 clinical trial for mRNA-1469, a vaccine candidate for the Bundibugyo ebolavirus. The program is supported by a partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), which has committed up to $50 million in funding.
Market Reaction
Thursday's price action demonstrates how sensitive vaccine-focused biotechnology stocks are to political and regulatory news. The potential for a shift in government policy was enough to outweigh a major commercial and clinical milestone for Moderna.
However, the stock did pare some of its losses in after-hours trading, gaining 1.6%. This modest recovery may indicate that some investors see the political threat as a temporary risk compared to the company's long-term fundamental progress in expanding its vaccine pipeline.
Read next
More on Stocks
FTC Orders Walmart, Uber, Delta to Disclose Data on Personalized Pricing
The U.S. Federal Trade Commission is demanding nine major companies, including leading retail, travel, and gig economy firms, to provide information on how they use consumer data for setting individual prices and wages.

Google Launches Gemini 4 Carbon AI Model to Bolster Cybersecurity Capabilities
Alphabet's Google has unveiled Gemini 4 Carbon, its latest AI model specifically designed for advanced cybersecurity tasks like vulnerability detection and secure code generation. The launch escalates competition with rivals OpenAI and Anthropic in the enterprise AI market.

Oracle Shares Surge After Unveiling $225 Billion Revenue Target for 2030
Oracle stock rose sharply after the company presented a long-term financial outlook targeting at least $225 billion in annual revenue by fiscal 2030, driven by its expanding AI infrastructure business.

DOJ Scrutinizes Nvidia's $12.9B Hugging Face Deal Amid Broader Antitrust Probe, Sources Say
The U.S. Department of Justice is reportedly examining Nvidia's planned $12.93 billion acquisition of AI platform Hugging Face as part of a wider, ongoing antitrust investigation into the chipmaker's market conduct.